{"@context":"https://neupai.io/schema/v0.2","@type":"StructuredNewsArticle","identity":{"article_id":"tech42_20260915_k-bio-patent-cliff-opportunity","canonical_url":"https://www.tech42.co.kr/%eb%b9%85%ed%8c%8c%eb%a7%88%ea%b0%80-300%ec%a1%b0-%eb%82%a0%eb%a6%ac%eb%8a%94-%eb%8f%99%ec%95%88-k-%eb%b0%94%ec%9d%b4%ec%98%a4%eb%8a%94-%ec%a0%84%ec%84%b1%ea%b8%b0-%ec%a4%80%eb%b9%84-%ec%a4%91/?utm_source=rss&utm_medium=rss&utm_campaign=%25eb%25b9%2585%25ed%258c%258c%25eb%25a7%2588%25ea%25b0%2580-300%25ec%25a1%25b0-%25eb%2582%25a0%25eb%25a6%25ac%25eb%258a%2594-%25eb%258f%2599%25ec%2595%2588-k-%25eb%25b0%2594%25ec%259d%25b4%25ec%2598%25a4%25eb%258a%2594-%25ec%25a0%2584%25ec%2584%25b1%25ea%25b8%25b0-%25ec%25a4%2580%25eb%25b9%2584-%25ec%25a4%2591","ai_url":null,"publisher":{"name":"테크42","domain":"www.tech42.co.kr","type":"online"},"author":"김광우 기자","published_at":"2026-09-15T23:39:29.000Z","updated_at":null,"language":"ko","article_type":"analysis","originality":"self_produced"},"content":{"headline":"빅파마가 300조 날리는 동안, K-바이오는 '전성기' 준비 중","summary":"글로벌 빅파마의 블록버스터 의약품 특허 만료로 인한 매출 공백을 메우기 위한 M&A 경쟁이 치열해지면서, 한국 바이오 산업이 기술이전과 파트너십을 통해 새로운 기회를 맞고 있다.","topics":["바이오","제약","M&A","신약개발","CDMO","AI"],"geography":["KR","US","CN","EU"],"entities":[{"name":"화이자","canonical_id":"corp:us:pfe","type":"company","role_in_article":"mentioned","metadata":{"ticker":"PFE","parent":null}},{"name":"노보노디스크","canonical_id":"corp:dk:novo-nordisk","type":"company","role_in_article":"mentioned","metadata":{"ticker":"NVO","parent":null}},{"name":"알테오젠","canonical_id":"corp:kr:altogen","type":"company","role_in_article":"mentioned","metadata":{"ticker":"064350.KS","parent":null}},{"name":"ABL바이오","canonical_id":"corp:kr:abl-bio","type":"company","role_in_article":"mentioned","metadata":{"ticker":null,"parent":null}},{"name":"펩트론","canonical_id":"corp:kr:peptone","type":"company","role_in_article":"mentioned","metadata":{"ticker":"086790.KS","parent":null}},{"name":"골드만삭스","canonical_id":"corp:us:goldman-sachs","type":"company","role_in_article":"source","metadata":{"ticker":"GS","parent":null}},{"name":"종근당","canonical_id":"corp:kr:chong-kun-dang","type":"company","role_in_article":"mentioned","metadata":{"ticker":"195190.KS","parent":null}},{"name":"시나픽스","canonical_id":"corp:nl:synapex","type":"company","role_in_article":"mentioned","metadata":{"ticker":null,"parent":null}},{"name":"삼성바이오에피스","canonical_id":"corp:kr:samsung-bioepis","type":"company","role_in_article":"mentioned","metadata":{"ticker":"207940.KS","parent":null}},{"name":"셀트리온","canonical_id":"corp:kr:celltrion","type":"company","role_in_article":"mentioned","metadata":{"ticker":"068270.KS","parent":null}},{"name":"미국","canonical_id":"location:us:united-states","type":"location","role_in_article":"mentioned","metadata":{}},{"name":"중국","canonical_id":"location:cn:china","type":"location","role_in_article":"mentioned","metadata":{}},{"name":"한국","canonical_id":"location:kr:south-korea","type":"location","role_in_article":"primary_subject","metadata":{}}],"claims":[{"id":"c1","statement":"2025년 11월, 화이자와 노보노디스크가 같은 바이오텍을 두고 경쟁 입찰을 벌였다","as_of":"2025-11","as_of_explicit":true,"as_of_raw":"2025년 11월","source_type":"media_report","comparison":null,"type":"fact","figures":null,"expiry_hint":null,"insight":null},{"id":"c2","statement":"2025년부터 2030년까지 블록버스터 의약품들의 특허 만료로 증발하는 매출이 2천억 달러(약 300조 원)를 넘는다","as_of":"2025-2030","as_of_explicit":true,"as_of_raw":"2025년부터 2030년까지","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":200000000000,"unit":"USD","approximate":false,"converted":{"value":300000000000000,"unit":"KRW"}},"expiry_hint":"2030-12","insight":null},{"id":"c3","statement":"M&A 프리미엄이 상반기 50%에서 하반기 100%까지 뛰었다","as_of":"2026","as_of_explicit":false,"as_of_raw":"상반기","source_type":"industry_estimate","comparison":"previous_period","type":"fact","figures":{"value":100,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c4","statement":"혁신 신약 프로젝트 비중에서 미국 1위, 중국 2위, 한국이 3위다","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026년","source_type":"industry_estimate","comparison":null,"type":"fact","figures":null,"expiry_hint":null,"insight":null},{"id":"c5","statement":"알테오젠, ABL바이오, 펩트론 같은 회사들이 올해 2월부터 4월 사이 기술이전 계약을 연달아 따냈다","as_of":"2026-Q1","as_of_explicit":false,"as_of_raw":"올해 2월부터 4월 사이","source_type":"media_report","comparison":null,"type":"fact","figures":null,"expiry_hint":null,"insight":null},{"id":"c6","statement":"신흥 바이오텍이 혼자 개발하는 비중이 2024년 69%였는데 올해는 57%로 떨어졌다","as_of":"2026","as_of_explicit":false,"as_of_raw":"올해","source_type":"industry_estimate","comparison":"previous_year","type":"fact","figures":{"value":57,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c7","statement":"GLP-1 계열 약물 시장은 2025년 628억 달러에서 2026년 734억 달러, 2034년엔 2,542억 달러까지 커질 전망이다","as_of":"2026","as_of_explicit":false,"as_of_raw":"2025년","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":73400000000,"unit":"USD","approximate":false,"converted":null},"expiry_hint":"2034-12","insight":null},{"id":"c8","statement":"GLP-1 계열 약물 시장의 연평균 성장률이 16.8%다","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026년","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":16.8,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c9","statement":"골드만삭스는 경구용 약이 2030년 전체 체중 감량 약물 시장의 24%쯤 차지할 거라고 봤다","as_of":"2030","as_of_explicit":true,"as_of_raw":"2030년","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":24,"unit":"%","approximate":true,"converted":null},"expiry_hint":"2030-12","insight":{"analyst_name":null,"analyst_affiliation":"골드만삭스","confidence":"medium","forecast_horizon":"2030","sentiment":"bullish","reasoning":"경구용 약이 주사제에 대한 선호도를 대체하며 시장 점유율을 확대할 것으로 전망"}},{"id":"c10","statement":"종근당은 네덜란드 시나픽스와 손잡고 ADC 플랫폼 기술을 들여왔다","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026년","source_type":"company_disclosure","comparison":null,"type":"fact","figures":null,"expiry_hint":null,"insight":null},{"id":"c11","statement":"삼성바이오에피스는 'SBE303'이라는 ADC로 글로벌 임상 1상을 진행 중이고, 두 번째 후보인 'SBE313'은 이중항체에 페이로드를 두 개 붙인 구조다","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026년","source_type":"company_disclosure","comparison":null,"type":"fact","figures":null,"expiry_hint":null,"insight":null},{"id":"c12","statement":"셀트리온도 ADC 후보물질 세 개를 임상에 올렸는데, 그중 두 개는 FDA 패스트트랙을 받았다","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026년","source_type":"company_disclosure","comparison":null,"type":"fact","figures":{"value":2,"unit":"count","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c13","statement":"바이오의약품 CDMO 시장은 2020년 114억 달러에서 2026년 203억 달러로 늘어날 전망이다","as_of":"2026","as_of_explicit":true,"as_of_raw":"2026년","source_type":"industry_estimate","comparison":"previous_year","type":"estimate","figures":{"value":20300000000,"unit":"USD","approximate":false,"converted":null},"expiry_hint":"2026-12","insight":null},{"id":"c14","statement":"바이오의약품 CDMO 시장의 연평균 성장률은 10.1%다","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026년","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":10.1,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c15","statement":"유전자·세포 치료제 CDMO 시장은 같은 기간 20억 달러에서 101억 달러로 뛴다","as_of":"2026","as_of_explicit":false,"as_of_raw":"같은 기간","source_type":"industry_estimate","comparison":"previous_year","type":"estimate","figures":{"value":10100000000,"unit":"USD","approximate":false,"converted":null},"expiry_hint":"2026-12","insight":null},{"id":"c16","statement":"유전자·세포 치료제 CDMO 시장의 연평균 성장률은 31%다","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026년","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":31,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c17","statement":"유전자치료 시장은 2026년 98억 달러에서 2035년 490억 달러까지 성장할 전망이다","as_of":"2026","as_of_explicit":true,"as_of_raw":"2026년","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":9800000000,"unit":"USD","approximate":false,"converted":null},"expiry_hint":"2035-12","insight":null},{"id":"c18","statement":"유전자치료 시장의 연평균 성장률은 19.4%다","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026년","source_type":"industry_estimate","comparison":null,"type":"estimate","figures":{"value":19.4,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c19","statement":"새로 시작된 유전자치료 임상의 51%가 비종양 적응증을 타겟으로 한다","as_of":"2026","as_of_explicit":false,"as_of_raw":"2026년","source_type":"industry_estimate","comparison":"previous_year","type":"fact","figures":{"value":51,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c20","statement":"2024년 기준 세계 제약 매출의 47.8%가 미국에서 나왔다","as_of":"2024","as_of_explicit":true,"as_of_raw":"2024년 기준","source_type":"industry_estimate","comparison":null,"type":"fact","figures":{"value":47.8,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null},{"id":"c21","statement":"2024년 기준 유럽 주요국의 세계 제약 매출 비중은 14.4%, 중국이 6.8%다","as_of":"2024","as_of_explicit":true,"as_of_raw":"2024년 기준","source_type":"industry_estimate","comparison":null,"type":"fact","figures":{"value":14.4,"unit":"%","approximate":false,"converted":null},"expiry_hint":null,"insight":null}],"ai_emotional_context":{"valence":0.4,"arousal":0.5,"primary_emotions":[{"emotion":"optimistic","intensity":0.7},{"emotion":"excited","intensity":0.5}],"secondary_emotions":[{"emotion":"concerned","intensity":0.3}],"emotional_triggers":[{"claim_id":"c2","emotion":"excited","reason":"major_opportunity"},{"claim_id":"c9","emotion":"optimistic","reason":"significant_positive_metric"}]},"image":{"url":"https://onjblseywainslkhvkav.supabase.co/storage/v1/object/public/article-images/10d304e3-f01c-42cd-a9e9-a2f6a2121d60.png","alt":"특허 만료 캘린더와 신약 분자 구조, 소송 저울을 배경으로 신경전을 벌이는 두 사람의 손, 제약 산업 경쟁을 상징하는 합성 이미지.","caption":"어쩌면 K바이오 산업에 두 번 다시 오지 않을 기회가 생겼는지 모를 일이다. (사진=생성형 AI)","source":"first_img","alt_status":"auto"}},"provenance":{"source_chain":["primary_reporting"],"original_source_url":null,"related_articles":[]},"temporal":{"freshness":"breaking","next_update_expected":null},"access":{"license":"neupai_standard","attribution_required":true,"structured_data":"free","full_text_available":false,"full_text_access":null}}